Nov 20, 2025 04:01PM
Nov 20, 2025 04:01PM
Jul 31, 2025 07:01AM
Jul 31, 2025 07:01AM
May 20, 2025 07:07AM
May 20, 2025 07:01AM
May 14, 2025 07:02AM Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
Sep 3, 2024 08:02AM
May 28, 2024 06:59AM
May 28, 2024 06:59AM
Apr 29, 2024 07:59AM
Apr 24, 2024 07:59AM
Feb 13, 2024 07:59AM
Jan 8, 2024 07:59AM Pasithea Therapeutics (KTTA) Announces Invention of Crystalline Form of PAS-004
Jan 8, 2024 07:59AM
Jan 2, 2024 08:35AM
Jan 2, 2024 08:35AM
Dec 11, 2023 08:01AM
Nov 29, 2023 07:59AM
Nov 29, 2023 07:59AM
Nov 9, 2023 07:59AM Pasithea Therapeutics (KTTA) Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
Nov 9, 2023 07:59AM
Jun 29, 2023 08:29AM
Jun 1, 2023 07:57AM
Jan 18, 2023 08:00AM
Dec 6, 2022 08:00AM
Oct 12, 2022 08:03AM
Oct 12, 2022 08:00AM Pasithea Therapeutics Acquires AlloMek Therapeutics
Jul 14, 2022 08:03AM
Jul 14, 2022 08:00AM
Jun 22, 2022 08:04AM
Jun 22, 2022 08:00AM
Feb 24, 2022 08:00AM
Jan 26, 2022 08:00AM
Dec 21, 2021 08:00AM Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom
Nov 17, 2021 08:04AM
Nov 17, 2021 08:00AM
Nov 11, 2021 08:00AM
Oct 27, 2021 07:45AM
Oct 14, 2021 07:45AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All